PL3826667T3 - Przeciwciała przeciwko klaudynie6 i sposoby leczenia nowotworu - Google Patents

Przeciwciała przeciwko klaudynie6 i sposoby leczenia nowotworu

Info

Publication number
PL3826667T3
PL3826667T3 PL18857242.4T PL18857242T PL3826667T3 PL 3826667 T3 PL3826667 T3 PL 3826667T3 PL 18857242 T PL18857242 T PL 18857242T PL 3826667 T3 PL3826667 T3 PL 3826667T3
Authority
PL
Poland
Prior art keywords
claudin6
antibodies
methods
treating cancer
cancer
Prior art date
Application number
PL18857242.4T
Other languages
English (en)
Polish (pl)
Inventor
Dylan CONKLIN
Dennis Slamon
Neil O'Brien
Mike PALAZZOLO
Erika VON EUW
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of PL3826667T3 publication Critical patent/PL3826667T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
PL18857242.4T 2017-09-18 2018-09-18 Przeciwciała przeciwko klaudynie6 i sposoby leczenia nowotworu PL3826667T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762560143P 2017-09-18 2017-09-18
PCT/US2018/051610 WO2019056023A2 (en) 2017-09-18 2018-09-18 ANTIBODIES AGAINST CLAUDIN 6 AND METHODS OF TREATING CANCER

Publications (1)

Publication Number Publication Date
PL3826667T3 true PL3826667T3 (pl) 2024-09-30

Family

ID=65723110

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18857242.4T PL3826667T3 (pl) 2017-09-18 2018-09-18 Przeciwciała przeciwko klaudynie6 i sposoby leczenia nowotworu

Country Status (22)

Country Link
US (4) US20200291111A1 (enExample)
EP (2) EP4435009A3 (enExample)
JP (2) JP7599332B2 (enExample)
KR (2) KR102793719B1 (enExample)
CN (2) CN118667021A (enExample)
AU (2) AU2018334434B2 (enExample)
BR (1) BR112020005196A2 (enExample)
CA (1) CA3076207A1 (enExample)
CZ (1) CZ2021138A3 (enExample)
DK (1) DK3826667T3 (enExample)
ES (1) ES2986343T3 (enExample)
FI (1) FI3826667T3 (enExample)
GB (1) GB202103867D0 (enExample)
HU (1) HUE067603T2 (enExample)
IL (2) IL313238A (enExample)
MX (2) MX2020002921A (enExample)
NO (1) NO20210351A1 (enExample)
PL (1) PL3826667T3 (enExample)
PT (1) PT3826667T (enExample)
SG (1) SG11202002114RA (enExample)
SI (1) SI3826667T1 (enExample)
WO (1) WO2019056023A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL313238A (en) * 2017-09-18 2024-07-01 Univ California Claudin6 antibodies and methods of treating cancer
CA3126646A1 (en) 2017-09-29 2019-04-04 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate
KR102063341B1 (ko) * 2018-12-31 2020-01-07 다이노나(주) Icam-1에 특이적으로 결합하는 항체 및 그의 용도
JP7570338B2 (ja) 2019-02-15 2024-10-21 インテグラル・モレキュラー・インコーポレイテッド クローディン６抗体及びその使用
JP7682797B2 (ja) * 2019-03-20 2025-05-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クローディン６二重特異性抗体
AU2020241896A1 (en) * 2019-03-20 2021-09-23 The Regents Of The University Of California Claudin-6 antibodies and drug conjugates
US11834512B2 (en) 2020-05-04 2023-12-05 The Regents Of The University Of California Inhibiting anti-ENPP1 antibodies
CN112386687B (zh) * 2020-12-09 2021-05-04 爱龄医美国际健康咨询服务(北京)有限公司 一种干细胞外泌体及其在药品和化妆品中的应用
WO2023091512A2 (en) * 2021-11-16 2023-05-25 Allakos, Inc. Antibodies to anti-siglec-9 and multispecific antibodies targeting siglec-7 and siglec-9
KR20240153421A (ko) * 2022-02-09 2024-10-22 세라 프로그노스틱스 인코포레이티드 Shbg 및 ibp4 항체 및 이를 사용하는 방법
IL319951A (en) 2022-11-30 2025-05-01 Integral Molecular Inc Antibodies targeting claudin 6, including its bispecific formats
US12403202B2 (en) 2023-05-25 2025-09-02 The Regents Of The University Of California Dosage of claudin-6 conjugates for cancer treatment
WO2025075127A1 (ja) * 2023-10-04 2025-04-10 公立大学法人福島県立医科大学 がんのバイオマーカー及び抗体治療
WO2025146161A1 (en) * 2024-01-04 2025-07-10 Hansoh Bio Llc Antibody, antigen-binding fragment and medical use thereof
WO2025162270A1 (zh) * 2024-02-01 2025-08-07 江苏恒瑞医药股份有限公司 抗cldn6抗体、其抗体-药物偶联物及其医药用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
ATE92499T1 (de) 1984-12-04 1993-08-15 Lilly Co Eli Tumorbehandlung bei saeugetieren.
EP1053752A1 (en) 1998-02-10 2000-11-22 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
AU756796B2 (en) 1998-10-16 2003-01-23 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Combination therapy with VIP antagonist
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
WO2003048731A2 (en) 2001-12-03 2003-06-12 Abgenix, Inc. Antibody categorization based on binding characteristics
DE60331455D1 (de) 2002-10-04 2010-04-08 Microchips Inc Medizinische vorrichtung zur gesteuerten arzneimittelverabreichung sowie herzüberwachung und/oder herzstimulation
CA2672581A1 (en) * 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
RU2422134C1 (ru) 2007-04-19 2011-06-27 Донг-А Фармасьютикал. Ко., Лтд Композиция биоразлагающихся микросфер, пригодная для контролируемого высвобождения контролирующего уровень глюкозы пептида, и ее состав
JP5848863B2 (ja) * 2008-01-11 2016-01-27 国立大学法人 東京大学 抗ｃｌｄｎ６抗体
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
CA2832174C (en) * 2011-05-13 2024-02-27 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
CA2928671A1 (en) * 2013-11-06 2015-05-14 Stemcentrx, Inc. Novel anti-claudin antibodies and methods of use
RS58627B2 (sr) * 2014-04-01 2022-06-30 Biontech Cell&Gene Therapies Gmbh Klaudin-6-specifični imuno receptori i t-ćelijski epitopi
IL313238A (en) * 2017-09-18 2024-07-01 Univ California Claudin6 antibodies and methods of treating cancer

Also Published As

Publication number Publication date
EP3826667A2 (en) 2021-06-02
KR20200070238A (ko) 2020-06-17
NO20210351A1 (en) 2021-03-18
JP2024150445A (ja) 2024-10-23
JP2020536507A (ja) 2020-12-17
FI3826667T3 (fi) 2024-07-22
SG11202002114RA (en) 2020-04-29
CZ2021138A3 (cs) 2021-09-15
KR20250050137A (ko) 2025-04-14
CN118667021A (zh) 2024-09-20
EP4435009A3 (en) 2025-02-26
MX2025012685A (es) 2025-11-03
CN111565744B (zh) 2024-12-31
CA3076207A1 (en) 2019-03-21
CN111565744A (zh) 2020-08-21
JP7599332B2 (ja) 2024-12-13
WO2019056023A2 (en) 2019-03-21
IL273196B2 (en) 2024-11-01
US20240400674A1 (en) 2024-12-05
AU2018334434B2 (en) 2025-01-23
GB202103867D0 (en) 2021-05-05
KR102793719B1 (ko) 2025-04-08
US20200291111A1 (en) 2020-09-17
US20250333501A1 (en) 2025-10-30
ES2986343T3 (es) 2024-11-11
EP3826667B1 (en) 2024-04-17
BR112020005196A2 (pt) 2020-09-15
DK3826667T3 (da) 2024-07-22
AU2025200467A1 (en) 2025-04-10
IL273196B1 (en) 2024-07-01
HUE067603T2 (hu) 2024-10-28
WO2019056023A3 (en) 2019-05-16
AU2018334434A1 (en) 2020-04-02
MX2020002921A (es) 2020-09-28
EP3826667A4 (en) 2022-07-27
IL313238A (en) 2024-07-01
EP4435009A2 (en) 2024-09-25
SI3826667T1 (sl) 2024-09-30
PT3826667T (pt) 2024-08-02
US20220372134A1 (en) 2022-11-24
IL273196A (en) 2020-04-30

Similar Documents

Publication Publication Date Title
IL273196A (en) Claudin 6 antibodies and methods of cancer treatment
IL267803A (en) Methods for treating cancer with anti-tim-3 antibodies
IL275663A (en) Cancer treatment methods
IL289663A (en) Claudin 18 antibodies and methods for cancer treatment
IL267804A (en) Methods for treating cancer with anti-pd-1 antibodies
SG10202110594UA (en) Methods of treating tumor
IL256025A (en) Methods of diagnosing and treating cancer
IL255569A (en) Methods of treating cancer using anti-ox40 antibodies
IL253462A0 (en) Cancer treatment with monoclonal antibodies against latency-associated peptide
IL266990A (en) Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens
IL262342A (en) Cancer treatment methods
IL277981A (en) Cancer treatment methods
ZA201802481B (en) Novel biomarkers and methods of treating cancer
IL323981A (en) Cancer treatment methods
SG11202010793UA (en) Methods of treating cancer
ZA201908539B (en) Method of treatment of cancer
IL272810A (en) Methods for diagnosing and treating lung cancer
SG11202005296SA (en) Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
ZA202002144B (en) Antibodies and methods of use
SG11202005163PA (en) Methods of treating cancer
EP3585819A4 (en) ANTIBODY CONSTRUCTIONS AND CANCER TREATMENT METHODS
IL269123A (en) Methods of treating cancer
GB201609402D0 (en) Materials and methods for treating cancer
HK40053388B (en) Claudin6 antibodies and methods of treating cancer
SG11202108140SA (en) Anti-bag2 antibody and methods of treating cancer